Global Hypercalcemia Treatment Market Set to Reach USD 55.07 Billion by 2033, Expanding at an 11.8% CAGR

Hypercalcemia Treatment Market

The global hypercalcemia treatment market is forecast to attain a valuation of USD 18.07 billion by the end of 2023. With an impressive compound annual growth rate (CAGR) of 11.8% over the next decade, the market is expected to reach USD 55.07 billion by 2033.

This growth is driven by the increasing prevalence of hypercalcemia, a condition often associated with cancer, kidney disease, and certain endocrine disorders. Additionally, the continuous advancements in treatment options, including medications and therapies that effectively manage calcium levels in the blood, are contributing to the market’s rapid expansion.

Hypercalcemia Treatment Market Trend Analysis

• Improvements in hypercalcemia prognosis and diagnosis procedures for early detection of high calcium levels in blood.
• Growing investment by market players in research activities for the development of novel and effective hypercalcemia medications.
• Collaboration of hospitals and other healthcare institutes with private players providing hypercalcemia pharmaceuticals.
• The proliferation of healthcare service-providing companies by the adoption of hypercalcemia emerging therapies.
• The increase in drug-related adverse effects has posed a significant challenge to hypercalcemia treatment services.

Market Analysis of Hypercalcemia Treatment Market from 2018 to 2022 vs. Market Outlook for 2023 to 2033

The market value for the hypercalcemia treatment was nearly US$ 25.3 billion which is 57.8% of the global endocrinology drugs market in 2022. According to a global market survey, overall demand for hypercalcemia treatment services, in terms of value was around US$ 9.64 billion in 2018.

There has been a stagnated rise across product segments of this market from 2018 and 2022. Further, the lockdown due to COVID-19 caused supply chain disruptions and discontinued business operations. As many biopharma companies had to wait for the availability of new batches of raw material for hypercalcemia drug production, the hypercalcemia treatment facilities also reduced their service offerings.

Competitive Landscape

Companies indulged in developing hypercalcemia drugs and treatment therapies are actively seeking to strengthen their position through approval, and agreements with established healthcare institutes. Also, collaborations, mergers & acquisition partnerships with regional players can accelerate their strategy to capture a significant share of the emerging markets.

The emergence of many biotech firms for conducting research and development on hypercalcemia diagnosis and therapy also could be a factor for further market growth. They are developing medicines and APIs manufactured in individual and combination doses for the treatment of hypercalcemia associated with thyroid tumors and other illnesses.

Key Developments

• In April 2021, Novartis AG announced a collaboration with Artios Pharma. This collaboration was made to improve both companies’ discovery platforms, leverage their knowledge, and improve the potential of radio ligand therapies for treating cancers of both companies.
• In June 2021, Bayer AG and Aurexel Life Sciences published their collaborative article reports where they announced promising results with the use of combination therapy of radium-223 and bortezomib. It was used for treating multiple myeloma bone disease.
• In September 2021, Sunovian Pharmaceuticals announced a joint development and collaboration with Otsuka Pharmaceutical Co. This collaboration was made as an effort to improve the research and development activities to improve their production of novel drug compounds.
• In January 2021, Bayer AG announced the USA FDA priority review for their New Drug Application for Finerenone drug used to treat patients with chronic kidney disease and associated Type 2 diabetes.

Key Companies Profiled

• Amgen Inc.
• Pfizer Inc.
• Mylan N. V.
• Sunovion
• Procter And Gamble
• Apotex Corporation
• Genentech, Inc.
• Novartis AG
• Bayer AG
• Hoffmann La Roche
• Atnahs Pharma
• Cipla Inc.
• Sun Pharmaceuticals Industries Ltd
• Dr. Reddy’s Laboratories
• Aurobindo Pharma Limited

Grab Your Complete Report Instantly

Key Market Segments Covered In Hypercalcemia Treatment Industry Research

By Product:

• Bisphosphonates
  • Clodronate
  • Ibandronate
  • Pamidronate
  • Zoledronic Acid
• Calcitonin
• Glucocorticoids
• Denosumab
• Calcimimetics

By Distribution Channel:

• Hospitals
• Clinics
• Independent Pharmacy & Drug Stores

By Region:

• North America
• Latin America
• Europe
• South Asia
• East Asia
• Oceania
• The Middle East and Africa (MEA)

Author By:

Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.

Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.

Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:        

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531

For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube